Search Results

A commercial-grade blueprint for the Ireland-India pharma corridor under the EU-India FTA: tariffs, HPRA-CDSCO bridges, 2030 projections, policy asks.

The historic UK-India Comprehensive Economic and Trade Agreement (CETA) and Double Contributions Convention have officially entered into force, opening duty-free access for pharmaceuticals, dismantling high tariffs on manufacturing inputs, and eliminating dual social security taxes for mobile professionals.

The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines — a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.

Discover how the monumental EU-India Free Trade Agreement creates a market of 2 billion people. Explore its impact on tech, education, and how it will specifically propel Ireland's pharmaceutical and life sciences sector.